Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sanara MedTech (SMTI) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Sanara MedTech (SMTI) over the last 11 years, with Q3 2025 value amounting to $1.1 million.

  • Sanara MedTech's Capital Expenditures rose 1154779.02% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.6 million, marking a year-over-year increase of 235576.69%. This contributed to the annual value of $205848.0 for FY2024, which is 2239.36% down from last year.
  • Sanara MedTech's Capital Expenditures amounted to $1.1 million in Q3 2025, which was up 1154779.02% from $1.8 million recorded in Q2 2025.
  • Sanara MedTech's Capital Expenditures' 5-year high stood at $1.8 million during Q2 2025, with a 5-year trough of $4391.0 in Q1 2021.
  • In the last 5 years, Sanara MedTech's Capital Expenditures had a median value of $53364.0 in 2022 and averaged $280708.8.
  • Per our database at Business Quant, Sanara MedTech's Capital Expenditures plummeted by 9465.95% in 2024 and then surged by 1154779.02% in 2025.
  • Quarter analysis of 5 years shows Sanara MedTech's Capital Expenditures stood at $141710.0 in 2021, then crashed by 62.34% to $53364.0 in 2022, then grew by 1.71% to $54276.0 in 2023, then soared by 32.97% to $72172.0 in 2024, then skyrocketed by 1368.0% to $1.1 million in 2025.
  • Its Capital Expenditures stands at $1.1 million for Q3 2025, versus $1.8 million for Q2 2025 and $1.7 million for Q1 2025.